Opportunity

RRPV #RRPV 27-08-AdjEgg

BARDA vaccine development, clinical testing, and potential licensure for an adjuvanted egg-based pandemic influenza vaccine

Buyer

Center for the Biomedical Advanced Research and Development Authority (BARDA)

Posted

November 20, 2026

Respond By

January 25, 2027

Identifier

RRPV 27-08-AdjEgg

NAICS

325414, 541714

BARDA is seeking a development partner to advance an adjuvanted, egg-based pandemic influenza vaccine toward potential FDA licensure. - Government buyer: U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), Contracts Management & Acquisition office. - OEMs and vendors: No vaccine manufacturer, OEM, or vendor is named. - Requested services: Develop and manufacture clinical trial material and adjuvant; conduct Phase 1/2 clinical studies and supporting immune-assay work; and provide regulatory and analytical development toward potential FDA licensure. - Potential additional work includes Phase 3 and pediatric trials, co-formulation, BLA preparation, domestic adjuvant manufacturing capability, and platform or delivery innovations. - Key requirements: Use an adjuvant included in a U.S.-licensed vaccine and an antigen made using a U.S.-licensed seasonal egg-based process. H5 influenza strains with pandemic potential are preferred; antigen selection will be negotiated. - Quantity and part number: No product quantities are specified. Solicitation reference: RRPV 27-08-AdjEgg. - Funding and term: Approximately $67 million–$410 million anticipated for one to two awards. Performance is expected to begin in FY 2027 and may continue for up to five years; specific dates will be negotiated.

Description

This Request for Project Proposals seeks to advance development of a sustainable, adjuvanted, egg-based pandemic influenza vaccine through clinical evaluation and potential FDA licensure. The work includes manufacturing process development and production of initial cGMP clinical trial material, early clinical studies to evaluate safety and immune response, and development of a regulatory strategy and submission package. The goal is a commercially viable vaccine and scalable domestic manufacturing capability to support pandemic response. The solicitation anticipates approximately $67 million to $410 million in U.S. Government funding and one to two awards.

View original listing